Used in cancer immunotherapy to modulate T cell activity, enhancing anti-tumor immune responses. Targets GITR (glucocorticoid-induced TNFR-related protein) on regulatory and effector T cells, promoting immune activation and suppressing tumor growth. Investigated for use in combination with other checkpoint inhibitors to improve therapeutic efficacy in solid tumors. Also applied in research settings to study immune regulation and develop novel biologics.